Slingshot members are tracking this event:

VX-661 and ivacaftor did not result in a pre-specified improvement in lung function in people with mutations that result in minimal CFTR function; Vertex plans to close this study based on the recommendation of the DSMB

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
VRTX Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 15, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Vx-661, Cftr Function, Dsmb, Termination